Not for release or distribution or publication in whole or part in or into the United States, Canada, Japan or Australia
|
11/17/2005 Press Release
BioAlliance Pharma SA Announces the Filing of Its Document de Base With the AMF in Connection With Its Planned IPO on Euronext
Paris, 17 November 2005— BioAlliance Pharma SA , a biopharmaceutical company focused on the development and commercialisation of innovative therapeutics in the field of drug resistance, announced today that it has filed its Document de Base with the French Autorité des Marchés Financiers (AMF) under number I. 05-132 dated November 15, 2005 as part of the Initial Public Offering of its shares on Euronext Eurolist Compartment C. The filing of the Document de Base is the first step in the IPO process under AMF rules.
This transaction should take place in early December 2005, in accordance with market conditions and subject to a visa (approval) by the AMF on the Company's prospectus.
The document de base may be obtained free of charge from BioAlliance Pharma as well as on the websites of BioAlliance Pharma (www.Bioalliancepharma.com) and the AMF (www.amf-france.org).
About BioAlliance Pharma
BioAlliance Pharma is a privately-held biopharmaceutical company specialised in the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections. The company is developing three broad product ranges based on the Lauriad ® adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug ® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities programme focused on development of new drugs in oncology and HIV.
The company’s most advanced product, the miconazole Lauriad® 50 mg Bioadhesive Buccal Tablet, has just completed Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In September 2005, this product was the subject of a request for Marketing Authorisation for Europe and a pivotal Phase III trial is expected to initiate in the US in 2006 for the same indication. A second product, acyclovir Lauriad®, for the treatment of oral herpes, has recently completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the company’s doxorubicin Transdrug® nanoparticle delivery technology is ongoing in Europe, and has been granted orphan drug status by the EMEA and the FDA.
This press release may not be transmitted and cannot constitute an offer of subscription or sale of shares in the countries where such an offer would violate applicable laws and regulations, including Australia, Canada, Japan and the United States of America. In particular, the shares of BioAlliance Pharma have not and will not be registered in the United States of America within the meaning of the Securities Act of 1933 as amended and will not be the subject of a public offering in the United States of America. Consequently, this press release may not be used for any offer or sale of shares in the United States of America unless such offer or sale is exempt from all applicable registration obligations. No communication relating to this public offering may be addressed to the United States of America or target the citizens of or persons residing or present in the United States of America.
For additional company background, click here.
Media and analysts contacts:
Piers Morgan
Chief Financial Officer
BioAlliance Pharma SA
Tel : +33 1 45 58 71 04
piers.morgan@bioalliancepharma.com
Andrew Lloyd & Associates
Andrew Lloyd, Gilles Pettitot
Tel : +33 1 56 54 07 00
allo@alla.com , gilles@alla.com
|
